Drugs / LINTUZUMAB ACTINIUM AC-225

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT06802523 Apr 2026 → Dec 2028 acute myeloid leukemia National Cancer Institute (NCI) Suspended No outcome recorded
Phase 1 NCT03441048 May 2018 → May 2024 acute myeloid leukemia Medical College of Wisconsin Completed No outcome recorded
Phase 1 NCT02998047 Dec 2016 → May 2020 plasma cell myeloma Actinium Pharmaceuticals Terminated No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT03932318 Mar → Dec 2023 acute myeloid leukemia Actinium Pharmaceuticals Withdrawn No outcome recorded
Phase 1/2 NCT03867682 Jan 2020 → Nov 2023 acute myeloid leukemia Actinium Pharmaceuticals Unknown No outcome recorded
Phase 1/2 NCT02575963 Oct 2012 → Nov 2018 acute myeloid leukemia Actinium Pharmaceuticals Completed No outcome recorded

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as LINTUZUMAB ACTINIUM AC-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as 225 Ac-lintuzumab “225 Actinium-lintuzumab (225 Ac-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33” PMID 33347715 Dec 2020
Known as 225 Actinium-lintuzumab 225 Actinium-lintuzumab (225 Ac-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33” PMID 33347715 Dec 2020
Known as 225ac-hum195 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Actimab-a ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Actinio (225ac) lintuzumab satetraxetan ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Actinium (225ac) lintuzumab satetraxetan ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Actinium ac 225 lintuzumab ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Actinium-225-labeled humanized anti-cd33 monoclonal antibody hum195 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Hum-195 ac-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as Lintuzumab AC 225 “This phase I trial tests the safety, side effects, and best dose of lintuzumab-Ac225 in combination with venetoclax and ASTX-727, and how well they work in treating patients...” NCT06802523
6

“Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.” NCT02998047

“Drug: Lintuzumab AC 225NCT02998047

NCT02575963

NCT03867682

NCT03441048

NCT03932318

Known as Lintuzumab satetraxetan ac-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Known as SGN-33 AC-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554
Action Deplete “highly cytotoxic alpha radiation emitter that targets the cluster of differentiation 33 (CD33) cell surface antigen, which is expressed on leukemic cells” NCT03441048
Modality Other / unclassified “Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.” NCT02998047
Route Intravenous “0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle” NCT02998047
Target CD33 “Lintuzumab attaches to CD33 positive cancer cells” NCT06802523